D.A. Davidson & CO. Has $87.18 Million Position in Johnson & Johnson (NYSE:JNJ)

D.A. Davidson & CO. raised its position in Johnson & Johnson (NYSE:JNJFree Report) by 2.2% in the 4th quarter, Holdings Channel reports. The firm owned 556,235 shares of the company’s stock after buying an additional 11,830 shares during the period. Johnson & Johnson accounts for approximately 0.9% of D.A. Davidson & CO.’s investment portfolio, making the stock its 19th biggest holding. D.A. Davidson & CO.’s holdings in Johnson & Johnson were worth $87,184,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Sachetta LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $1,009,000. Clearbridge Investments LLC increased its position in shares of Johnson & Johnson by 0.8% during the fourth quarter. Clearbridge Investments LLC now owns 6,285,184 shares of the company’s stock worth $985,140,000 after acquiring an additional 50,822 shares in the last quarter. Balentine LLC increased its position in shares of Johnson & Johnson by 0.3% during the fourth quarter. Balentine LLC now owns 83,742 shares of the company’s stock worth $13,126,000 after acquiring an additional 224 shares in the last quarter. Maj Invest Holding A S bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $70,212,000. Finally, Mckinley Capital Management LLC increased its position in shares of Johnson & Johnson by 2.4% during the fourth quarter. Mckinley Capital Management LLC now owns 6,936 shares of the company’s stock worth $1,087,000 after acquiring an additional 160 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on JNJ. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research report on Thursday, May 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Monday, May 6th. Bank of America decreased their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their target price for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $175.86.

Check Out Our Latest Stock Analysis on Johnson & Johnson

Johnson & Johnson Price Performance

NYSE:JNJ opened at $151.72 on Wednesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97. The firm has a market cap of $365.14 billion, a price-to-earnings ratio of 9.43, a P/E/G ratio of 2.49 and a beta of 0.55. The firm’s 50-day simple moving average is $151.88 and its 200 day simple moving average is $155.12.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. During the same period last year, the firm earned $2.68 EPS. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. As a group, sell-side analysts predict that Johnson & Johnson will post 10.64 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.27%. Johnson & Johnson’s payout ratio is 30.92%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.